Skip to main content
    B

    Balchem Corporation (BCPC)

    Official site

    BASIC MATERIALS • SPECIALTY CHEMICALS • NASDAQ

    $171.48
    -1.66 (-0.96%)

    Market Cap: $5.52B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Balchem Corporation (BCPC) Earnings: Report Dates and Results

    Updated Oct 23, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Balchem (BCPC) is expected to report earnings on Feb 18, 2027. In the quarter ended Sep 30, 2026, Balchem reported EPS of $1.57, above the $1.54 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    80%(32/40)
    Avg Surprise
    +5.74%
    Streak
    2 Q

    Upcoming Estimates

    Reports Feb 18, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$1.49
    Range$1.43 - $1.54
    5 analysts
    Revenue Consensus
    $292.65M
    Range$273.32M - $312.06M
    5 analysts
    Reports Apr 28, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$1.48
    Range$1.47 - $1.48
    2 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$1.44+2.4%
    60d ago$1.43+3.1%
    30d ago$1.43+3.1%
    7d ago$1.43+3.1%
    Current$1.48
    Revenue Consensus
    $284.61M
    Range$280.10M - $288.24M
    3 analysts

    Next Report

    BCPC has an expected report date of Feb 18, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 13.7% above the $1.31 reported for the quarter ended Dec 31, 2025.

    BCPC Earnings Call

    The latest BCPC earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, BCPC beat 32, missed 3 and matched 5. Revenue for the quarter ended Sep 30, 2026 was $290.66M, up 8.6% from $267.56M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$1.57$1.54$1.51 - $1.56+1.95%Beat+16.3%22 up, 0 downOct 23, 2026$290.66M
    Jun 30, 2026$1.49$1.40N/A+6.43%Beat+17.3%21 up, 0 downJul 31, 2026$284.00M
    Mar 31, 2026$1.33$1.33$1.32 - $1.340.00%In line+9.0%22 up, 0 downApr 30, 2026$270.71M
    Dec 31, 2025$1.31$1.18N/A+11.02%Beat+15.9%21 up, 1 downFeb 20, 2026$263.62M
    Sep 30, 2025$1.35$1.31$1.26 - $1.36+3.05%Beat+19.5%20 up, 1 downOct 21, 2025$267.56M
    Jun 30, 2025$1.27$1.25$1.25 - $1.25+1.60%Beat+16.5%20 up, 2 downJul 31, 2025$255.47M
    Mar 31, 2025$1.22$1.22$1.18 - $1.250.00%In line+18.4%21 up, 0 downApr 24, 2025$250.52M
    Dec 31, 2024$1.13$1.11$1.10 - $1.11+2.26%Beat+18.9%20 up, 2 downFeb 21, 2025$240.00M
    Sep 30, 2024$1.13$1.12$1.10 - $1.12+0.89%Beat+8.7%20 up, 0 downOct 25, 2024$239.94M
    Jun 30, 2024$1.09$1.03$1.03 - $1.04+5.83%Beat+2.8%21 up, 0 downJul 26, 2024$234.08M
    Mar 31, 2024$1.03$0.98$0.98 - $0.98+5.10%Beat+9.6%20 up, 0 downMay 3, 2024$239.66M
    Dec 31, 2023$0.95$0.93$0.85 - $1.01+2.15%Beat+1.1%20 up, 0 downFeb 16, 2024$228.70M
    Sep 30, 2023$1.04$0.97$0.89 - $1.05+7.22%Beat+4.0%20 up, 0 downOct 27, 2023$229.95M
    Jun 30, 2023$1.06$0.93$0.75 - $0.93+13.98%Beat-0.9%20 up, 0 downJul 28, 2023$231.25M
    Mar 31, 2023$0.94$0.82N/A+14.63%Beat-8.7%20 up, 0 downApr 28, 2023$232.54M
    Dec 31, 2022$0.94$0.83$0.69 - $0.91+13.25%Beat+10.6%30 up, 0 downFeb 24, 2023$232.53M
    Sep 30, 2022$1.00$1.03N/A-2.91%Miss+8.7%30 up, 0 downNov 4, 2022$244.27M
    Jun 30, 2022$1.07$1.00$1.00 - $1.00+7.00%Beat+15.1%10 up, 0 downJul 29, 2022$236.69M
    Mar 31, 2022$1.03$0.92$0.72 - $0.92+11.96%Beat+18.4%20 up, 0 downApr 29, 2022$228.87M
    Dec 31, 2021$0.85$0.85$0.85 - $0.850.00%In line+2.4%1N/AFeb 18, 2022$213.13M
    Sep 30, 2021$0.92$0.94$0.90 - $0.98-2.13%Miss+10.8%20 up, 0 downOct 29, 2021$197.87M
    Jun 30, 2021$0.93$0.88$0.84 - $0.92+5.68%Beat+9.4%2N/AJul 30, 2021$202.37M
    Mar 31, 2021$0.87$0.85$0.79 - $0.90+2.35%Beat+7.4%2N/AApr 30, 2021$185.66M
    Dec 31, 2020$0.83$0.81$0.76 - $0.85+2.47%Beat-5.7%2N/AFeb 19, 2021$180.71M
    Sep 30, 2020$0.83$0.78$0.61 - $0.79+6.41%Beat+2.5%2N/AOct 28, 2020$175.14M
    Jun 30, 2020$0.85$0.55$0.55 - $0.57+54.55%Beat+10.4%2N/AJul 31, 2020$173.35M
    Mar 31, 2020$0.81$0.78N/A+3.85%Beat+11.0%2N/AMay 1, 2020$174.44M
    Dec 31, 2019$0.88$0.84$0.84 - $0.84+4.76%Beat+14.3%1N/AFeb 21, 2020$166.53M
    Sep 30, 2019$0.81$0.74$0.74 - $0.74+9.46%Beat+11.0%1N/ANov 5, 2019$158.59M
    Jun 30, 2019$0.77$0.76$0.65 - $0.78+1.32%Beat+1.3%2N/AAug 1, 2019$161.55M
    Mar 31, 2019$0.73$0.73N/A0.00%In line-3.9%2N/AMay 3, 2019$157.03M
    Dec 31, 2018$0.77$0.69$0.52 - $0.80+11.59%Beat+13.2%3N/AFeb 28, 2019$163.54M
    Sep 30, 2018$0.73$0.73$0.57 - $0.730.00%In line+15.9%2N/ANov 6, 2018$155.04M
    Jun 30, 2018$0.76$0.74$0.74 - $0.77+2.70%Beat+18.8%2N/AAug 3, 2018$163.69M
    Mar 31, 2018$0.76$0.70$0.70 - $0.71+8.57%Beat+28.8%2N/AMay 4, 2018$161.41M
    Dec 31, 2017$0.68$0.62$0.61 - $0.64+9.68%Beat+1.5%3N/AFeb 27, 2018$159.26M
    Sep 30, 2017$0.63$0.62$0.61 - $0.63+1.61%Beat+3.3%3N/ANov 7, 2017$150.72M
    Jun 30, 2017$0.64$0.63$0.61 - $0.65+1.59%Beat-3.0%3N/AAug 4, 2017$147.08M
    Mar 31, 2017$0.59$0.61N/A-3.28%Miss+1.7%N/AN/AMay 9, 2017$137.73M
    Dec 31, 2016$0.67$0.65N/A+3.08%Beat+1.5%N/AN/AFeb 28, 2017$140.76M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $5.15, up 17.6% from the year before. It was $2.52 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$5.15+17.6%
    Dec 31, 2024$4.38+9.8%
    Dec 31, 2023$3.99-1.2%
    Dec 31, 2022$4.04+13.2%
    Dec 31, 2021$3.57+7.5%
    Dec 31, 2020$3.32+4.1%
    Dec 31, 2019$3.19+5.6%
    Dec 31, 2018$3.02+18.9%
    Dec 31, 2017$2.54N/A
    Dec 31, 2016$2.52N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,200 words across 6 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20265,2446
    2026Q2Jun 30, 20263,8416
    2026Q1Mar 31, 20265,5207
    2025Q4Dec 31, 20256,5957
    2025Q3Sep 30, 20255,4406
    2025Q2Jun 30, 20255,0587
    2025Q1Mar 31, 20254,5856
    2024Q4Dec 31, 20245,1736

    2026Q3 Earnings Call

    Opening remarks

    Carl Martin Bengtsson CFO Thank you. Good morning, everyone. Thank you for joining our conference call this morning to discuss the results of Balchem Corporation for the quarter ending September 30, 2026. My name is Martin Bengtsson, Chief Financial Officer, and hosting this call with me is Ted Harris, our Chairman, President, and CEO. Following the advice of our counsel, auditors, and the SEC, at this time I would like to read our forward-looking statement. Statements made in today's call that are not historical facts are considered forward-looking statements. We can give no assurance that the expectations reflected in forward-looking statements will prove correct, and various factors could cause actual results to differ materially from our expectations, including risks and factors identified in Balchem's most recent Form 10-K, 10-Q, and 8-K reports. The company assumes no obligation to update these forward-looking statements. Our commentary also includes non-GAAP financial measures. Please refer to the reconciliations in our earnings release for further details. I will now turn the call over to Ted Harris, our Chairman, President, and CEO.

    Theodore L. Harris Chairman, President, and CEO Thanks, Martin. Good morning, and welcome to our conference call. We were very pleased with our third-quarter results reported earlier this morning. They were once again driven by healthy, broad-based growth across all three of our reporting segments and continued solid execution on our strategic growth initiatives. Our healthy growth continues to be fueled by the ongoing market penetration of our unique portfolio of specialty nutrients and delivery systems, and the favorable better-for-you trends within the food and nutrition markets that are well aligned with our product offerings and capabilities. As a result, we delivered record quarterly consolidated sales, net earnings, and adjusted EBITDA, as well as solid cash flows. Before discussing our third-quarter financial results in more detail, I would like to provide a few comments on the current market environment within which we are operating, and also provide you with some updates regarding new science that has been recently published supporting our branded ingredients VitaCholine, K2VITAL, and K2VITAL DELTA. We continue to see healthy demand trends across the majority of our businesses. Within human nutrition and health, we continue to see solid demand growth for our unique portfolio of ingredients and solutions. Consumer interest in supplementation and better-for-you food systems continues to support a healthy market environment for us. In animal nutrition and health, momentum continues to build. Both ruminant and monogastric customers continue to adopt our nutrient technologies as they look for cost-effective ways to improve animal health and productivity. Within specialty products, we continue to see healthy market demand for our specialized performance gases and services.

    Frequently Asked Questions About BCPC

    When is Balchem's next earnings date?

    Balchem's next earnings report is expected for Feb 18, 2027.

    Did BCPC beat earnings estimates last quarter?

    Yes. Balchem reported EPS of $1.57 for the quarter ended Sep 30, 2026, above the $1.54 estimate, a 1.95% surprise.

    What EPS do analysts expect from BCPC next quarter?

    The consensus EPS estimate for Balchem for the quarter ending Dec 31, 2026 is $1.49 from 5 analysts, with estimates from $1.43 to $1.54.

    How often does BCPC beat earnings estimates?

    Balchem beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +3.29%.